Literature DB >> 28674022

FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.

Tong Liu1, Hao Zhang2, Li Sun3, Danyu Zhao4, Peng Liu3, Meisi Yan5, Neeha Zaidi6, Sudeh Izadmehr7, Animesh Gupta3, Wahid Abu-Amer3, Minna Luo8, Jie Yang2, Xunyan Ou2, Yining Wang2, Xuefeng Bai9, Yan Wang9, Maria I New10, Mone Zaidi3,7, Tony Yuen11, Caigang Liu12.   

Abstract

Fibrous sheath interacting protein 1 (FSIP1), a spermatogenesis-related testicular antigen, is expressed in abundance in breast cancers, particularly in those overexpressing human epidermal growth factor receptor 2 (HER2); however, little is known about its role in regulating the growth and metastasis of breast cancer cells. We and others have shown previously that FSIP1 expression in breast cancer correlates positively with HER2-positivity, recurrence, and metastases and negatively with survival. Here, using coimmunoprecipitation and microscale thermophoresis, we find that FSIP1 binds to the intracellular domain of HER2 directly. We further show that shRNA-induced FSIP1 knockdown in SKBR3 and MCF-7 breast cancer cells inhibits proliferation, stimulates apoptosis, attenuates epithelial-mesenchymal transition, and impairs migration and invasiveness. Consistent with reduced proliferation and enhanced apoptosis, xenotransplantation of SKBR3 cells stably transfected with sh-FSIP1 into nu/nu mice results in reduced tumor volumes compared with sh-NC transplants. Furthermore, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) mapping using sh-FSIP1 gene signature yielded associations with extracellular matrix protein pathways, and a reduction in SNAI2 protein expression was confirmed on Western blot analysis. Complementarily, interrogation of the Connectivity Map using the same gene signature yielded, as top hits, chemicals known to inhibit epithelial-mesenchymal transition, including rapamycin, 17-N-allylamino-17-demethoxygeldanamycin, and LY294002. These compounds phenocopy the effects of sh-FSIP1 on SKBR3 cell viability. Thus, FSIP1 suppression limits oncogenesis and invasiveness in breast cancer cells and, considering its absence in most other tissues, including normal breast, may become a potential target for breast cancer therapy.

Entities:  

Keywords:  GO analysis; KEGG pathway analysis; breast cancer therapeutics; gene expression signature

Mesh:

Substances:

Year:  2017        PMID: 28674022      PMCID: PMC5530656          DOI: 10.1073/pnas.1621486114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

2.  The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells.

Authors:  E Batlle; E Sancho; C Francí; D Domínguez; M Monfar; J Baulida; A García De Herreros
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

Review 3.  Regulatory subunits of PKA and breast cancer.

Authors:  W R Miller
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

4.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro.

Authors:  Chun-Chi Liang; Ann Y Park; Jun-Lin Guan
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

5.  Past, present, and future challenges in breast cancer treatment.

Authors:  George W Sledge; Eleftherios P Mamounas; Gabriel N Hortobagyi; Harold J Burstein; Pamela J Goodwin; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

6.  Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.

Authors:  Ajaya Kumar Reka; Rork Kuick; Himabindu Kurapati; Theodore J Standiford; Gilbert S Omenn; Venkateshwar G Keshamouni
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

7.  Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.

Authors:  Agnes Stachnik; Tony Yuen; Jameel Iqbal; Miriam Sgobba; Yogesh Gupta; Ping Lu; Graziana Colaianni; Yaoting Ji; Ling-Ling Zhu; Se-Min Kim; Jianhua Li; Peng Liu; Sudeh Izadmehr; Jaya Sangodkar; Thomas Scherer; Shiraz Mujtaba; Matthew Galsky; Jorge Gomez; Solomon Epstein; Christoph Buettner; Zhuan Bian; Alberta Zallone; Aneel K Aggarwal; Shozeb Haider; Maria I New; Li Sun; Goutham Narla; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

8.  Interplay of PI3K and cAMP/PKA signaling, and rapamycin-hypersensitivity in TGFbeta1 enhancement of FSH-stimulated steroidogenesis in rat ovarian granulosa cells.

Authors:  Yun-Ju Chen; Pei-Wen Hsiao; Ming-Ting Lee; J Ian Mason; Ferng-Chun Ke; Jiuan-Jiuan Hwang
Journal:  J Endocrinol       Date:  2007-02       Impact factor: 4.286

9.  Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines.

Authors:  Long Gu; Sean K Lau; Sofia Loera; George Somlo; Susan E Kane
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

10.  Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition.

Authors:  Melissa G Mendez; Shin-Ichiro Kojima; Robert D Goldman
Journal:  FASEB J       Date:  2010-01-22       Impact factor: 5.191

View more
  8 in total

1.  FSIP1 regulates autophagy in breast cancer.

Authors:  Caigang Liu; Lisha Sun; Jie Yang; Tong Liu; Yongliang Yang; Se-Min Kim; Xunyan Ou; Yining Wang; Li Sun; Mone Zaidi; Maria I New; Tony Yuen; Qiyong Guo
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-03       Impact factor: 11.205

2.  FSIP1 Is Associated with Poor Prognosis and Can Be Used to Construct a Prognostic Model in Gastric Cancer.

Authors:  Xiuchun Yan; Junzhu Dai; Ying Han; Qi You; Yao Liu
Journal:  Dis Markers       Date:  2022-06-03       Impact factor: 3.464

3.  Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations.

Authors:  Tatiana V Karpinets; Yoshitsugu Mitani; Bin Liu; Jianhua Zhang; Kristen B Pytynia; Linton D Sellen; Danice T Karagiannis; Renata Ferrarotto; Andrew P Futreal; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2021-05-19       Impact factor: 12.531

4.  Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients.

Authors:  Meritxell Arenas; Anabel García-Heredia; Noemí Cabré; Fedra Luciano-Mateo; Anna Hernández-Aguilera; Sebastià Sabater; Marta Bonet; Marina Gascón; Salvador Fernández-Arroyo; Isabel Fort-Gallifa; Jordi Camps; Jorge Joven
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

5.  Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.

Authors:  Meisi Yan; Jinsong Wang; Yanlv Ren; Lin Li; Weidan He; Ying Zhang; Tong Liu; Zhigao Li
Journal:  Cell Death Dis       Date:  2019-02-27       Impact factor: 8.469

6.  Cadmium Toxicity Is Regulated by Peroxisome Proliferator-Activated Receptor δ in Human Proximal Tubular Cells.

Authors:  Chikage Mori; Jin-Yong Lee; Maki Tokumoto; Masahiko Satoh
Journal:  Int J Mol Sci       Date:  2022-08-03       Impact factor: 6.208

7.  Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases.

Authors:  Xiaohe Li; Yinshan Fang; Dingyuan Jiang; Yingying Dong; Yingying Liu; Si Zhang; Jiasen Guo; Chao Qi; Chenjing Zhao; Fangxin Jiang; Yueyue Jin; Jing Geng; Cheng Yang; Hongkai Zhang; Bin Wei; Jiurong Liang; Chen Wang; Huaping Dai; Honggang Zhou; Dianhua Jiang; Wen Ning
Journal:  Mol Ther       Date:  2020-09-23       Impact factor: 11.454

8.  Discrete functional and mechanistic roles of chromodomain Y-like 2 (CDYL2) transcript variants in breast cancer growth and metastasis.

Authors:  Li-Feng Yang; Fan Yang; Fang-Lin Zhang; Yi-Fan Xie; Zhi-Xiang Hu; Sheng-Lin Huang; Zhi-Min Shao; Da-Qiang Li
Journal:  Theranostics       Date:  2020-04-06       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.